BLASUBCUTANEOUSINJECTION
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
16
Data completeness
3/8 — Basic
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EXDENSUR (depemokimab) is a monoclonal antibody (mAb) approved by the FDA in December 2025 as a subcutaneous injection. The specific indication and mechanism of action are not yet disclosed in available data. Patient population and therapeutic application require clinical trial data review.
Launch
Early-stage launch product with moderate competitive pressure (30/100) suggests a focused commercial team building market presence in a moderately crowded space.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (16)
Efficacy and Safety of Depemokimab Monotherapy Without Concomitant Use of Intranasal Corticosteroids (INCS) in Japanese Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Started Jul 2026
28 enrolled
Nasal Polyps
A Study of Depemokimab in Participants of 6 to 11 Years of Age
Started Jun 2026
34 enrolled
Asthma
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
Started Mar 2026
456 enrolled
Asthma
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
Started Oct 2025
1,196 enrolled
Pulmonary Disease, Chronic Obstructive
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
Started Jun 2025
960 enrolled
Pulmonary Disease, Chronic Obstructive
Worked on EXDENSUR at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.